bioRxiv / medRxiv
open access
A randomized, phase IIa treatment delayed-start trial of the oral JAK 1/2 inhibitor, baricitinib, in adult idiopathic inflammatory myopathy
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM#828614
- Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience#261986
- JAK inhibitor, a new player for treatment-refractory microscopic colitis#223193
- A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis#877680
- JAK Inhibition in Ulcerative Colitis#1173563
Record · ID 619208
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive